# A Study of Zetomipzomib (KZR-616) in Patients With Active Lupus Nephritis (PALIZADE)

> **NCT05781750** · PHASE2 · TERMINATED · sponsor: **Kezar Life Sciences, Inc.** · enrollment: 84 (actual)

## Conditions studied

- Lupus Nephritis

## Interventions

- **DRUG:** zetomipzomib
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT05781750
- **Lead sponsor:** Kezar Life Sciences, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2023-11-03
- **Primary completion:** 2024-11-08
- **Final completion:** 2024-11-08
- **Target enrollment:** 84 (ACTUAL)
- **Why stopped:** Sponsor Decision.
- **Last updated:** 2025-12-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05781750

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05781750, "A Study of Zetomipzomib (KZR-616) in Patients With Active Lupus Nephritis (PALIZADE)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05781750. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*